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ABSTRACT
Stimulation of mammalian cells frequently initiates phospholipase D-catalysed 
hydrolysis of phosphatidylcholine in the plasma membrane to yield phosphatidic acid 
(PA) a novel lipid messenger. PA plays a regulatory role in important cellular 
processes such as secretion, cellular shape change and movement. A number of 
studies have highlighted that PLD-based signalling also plays a pro-mitogenic and 
pro-survival role in cells and therefore anti-apoptotic. We show that human PLD1b 
and PLD2a contain functional caspase-3 cleavage sites and identify the critical 
aspartate residues within PLD1b that affect its activation by phorbol esters and 
attenuate phosphatidylcholine hydrolysis during apoptosis. 
1. INTRODUCTION
In mammalian cells, many agonists stimulate concurrent activation of 
phospholipase C (PLC), phospholipase A2 (PLA2) phosphatidylinositol 3-kinase and 
phospholipase D (PLD)-catalysed hydrolysis of phosphatidylcholine (PtdCho) to yield 
the novel lipid messenger phosphatidic acid (PA) [1-3]. In human cells, PLD1b and 
PLD2a are the most commonly expressed variants; both contain the characteristic 
HKD catalytic triad (the ‘PLD domain’) characteristic of members of the PLD-
superfamily and have similar domain structures [1,2,4]. The role of ADP-ribosylation 
factors (Arfs), the Rho-family of proteins, protein kinase C (PKC) and 
polyphosphoinositides in regulating phospholipase D activity and localisation is now 
largely understood [1,2, 5-7]. 
PLD-catalysed PtdCho hydrolysis plays a regulatory role in important 
processes such as the oxidative burst in neutrophils [8,9], secretion [10-12], 
mitogenesis [13,14] and cellular shape change and adhesion [15-17]. 
Changes in the dynamics of the actin cytoskeleton may represent the common target 
for PLD signalling for at least some of these processes [15]. We have recently shown 
a functional link between role and regulation of PLD1b through association with F-
actin during antigen-induced secretion in RBL-2H3 cells [17]. 
Apoptosis is a highly regulated pathway for cellular execution, initiated by 
changes in the balance of pro-mitogenic/differentiation signals versus pro-death 
signals [3, 18,19] that is characterised by membrane blebbing, phosphatidylserine 
exposure, cytosolic shrinkage, mitochondrial and nuclear disruption[18,19]. Apoptotic 
cell death is implemented following auto-activation of a class of cysteine proteases 
(caspases), which specifically cleave protein targets containing appropriate aspartate 
residue within consensus motifs [19,20]. Ligation of cell-surface death receptors leads 
to recruitment of adaptor proteins and subsequent activation of caspase-8 that 
converts inactive caspases-3 and -7 to the active forms, which execute the apoptotic 
program [18-22]. Known caspase substrates include cell adhesion molecules (e.g. 
Cadherins), cytoskeletal proteins (e.g. actin and gelsolin), nuclear proteins (lamins), 
cell-cycle proteins (cyclin A/E), DNA metabolising enzymes (PARP), transcription 
factors (NF-kB) and signal transduction proteins including receptors, adaptors, 
kinases, phosphatases and PLA2 [21,22].
In some cells phosphatidylcholine hydrolysis has been reported to increase 
during apoptosis [23-25], whereas in others PLD activity has been reported to 
decrease [26-28].  Furthermore, inhibiting PLD activity can initiate apoptosis [29,30] 
with over-expression of PLD1 or PLD2 protecting various cancerous cells from 
apoptosis [31-34], possibly via mechanisms that stabilises p53 via activation of mToR 
[35,36] and/or Raf1 or Ral [33]. Thus PLD-based signalling is most likely to be pro-
survival and anti-apoptotic [1-3, 25-35]. It is possible that PLD represents a legitimate 
target for the apoptotic machinery to enable plasma membrane remodelling [2] and 
necessary disruption of the cytoskeleton. Recently, PLD1 signalling has been shown 
to be anti-apoptotic in calphostin-c treated smooth muscle cells and inhibition of PLD 
activity by calphostin-c promoted inhibition of microtubule reorganisation [37]. Here 
we show that human PLD1b and PLD2a contain functional caspase-3 cleavage sites 
and identify the critical aspartate residues within PLD1b that affect its activation by 
phorbol esters and attenuate phosphatidylcholine hydrolysis during apoptosis. 
2. MATERIAL AND METHODS
Bioinformatic analysis of phospholipase sequences.
Sequences for human PLD1 (accession number Q13393-2) and PLD2 (accession 
number O14939), rodent phospholipases D, phopholipase C and phospholipase A2 
were analysed using the Predictor of Protease Specificity (PoPS) web-based 
bioinformatics tool from Monash University (http://pops.csse.monash.edu.au/). PoPS 
provides an arithmetic score for detected sites based on the consensus sequences for 
the selected protease. Five residues are used by the program to score a caspase-3 site 
within a sequence; these are the 4 residues N-terminal of the cleaved peptide bond 
(S1-S4) and the first C-terminal residue (S1’). An ideal caspase site would score 25 
and weak sites can be filtered from the report using a selected threshold, which was 
specified at 15 in this study. Results from the PoPS were compared to motif searching 
within the phospholipase D sequences using 4 residue caspase sites with the 
consensus sequence of DXXD or D/E, D/E, X, D [20].
Generation of vectors expressing GFP-PLD mutatants
The open readings frames (ORF) for human PLD1b or PLD2a were cloned in to 
pcDNA3.1 with an N-terminal GFP tag. Regions from PLD1b or PLD2a were sub-
cloned in to pBluescript using convenient restriction sites and specified aspartate 
codons changed to alanine by site-directed PCR mutagenesis. The sub-cloned 
fragments were re-inserted in to the appropriate human PLD ORF in pcDNA3.1. The 
presence of the mutation within the reconstructed ORF was confirmed by sequencing. 
Digestion of in vitro-produced PLD proteins by Caspase 3
2g plasmid mini-prep DNA (pcDNA3.1 harbouring GFP-PLD1b/PLD2a or mutants; 
predicted molecular weights of 148kDa and 134kDa respectively) was incubated with 
coupled in vitro transcription and translation reagent (Promega) and Ci []S-
methionine (90 minutes at 30oC).  Produced PLD proteins were incubated with 25nM 
caspase-3 (Biomol) in assay buffer (50mM HEPES pH7.4, 100mM NaCl, 0.1% 
CHAPS, 1mM EDTA, 10% glycerol, 10mM DTT). The competitive inhibitor Acetyl-
DDVD-Cho (Pharmingen) was incubated with caspase for 15 minutes prior to mixing 
with substrates. Proteins were separated by SDS-PAGE (4-12% Tris-glycine gels) and 
stained with coomassie blue dye.  Dried gels were exposed to a storage phosphor 
screen (Molecular Probes) for 90 minutes before visualisation and quantification of 
radioactivity (Total-Lab v1). Radioactivity per band was plotted as a percentage of 
total radioactivity per lane (units). Recombinant PLD1b was produced as described 
[6,17], digested with caspase 3 (as above) and fragments identified by western 
blotting using the specified antibodies. 
Cell culture and transfection
HEK-293 cells, grown in Dulbecco’s modified eagles medium (DMEM) with 
pyruvate and glutamax (Invitrogen), plus foetal calf serum (10%v/v), penicillin (100U) 
and streptomycin (100mg/ml) at 37oC in humidified 5% CO2 and passaged at 90% 
confluency. Two hours prior to transfection growth media was substituted for DMEM 
without additions. Transfection complexes were prepared in DMEM (without 
additions) by complexing 6g DNA with 6l Plus™ reagent for 15 minutes followed 
by 5l of Lipofectamine (Invitrogen) in a final volume of 100l and incubated with 
cells for 4 hours before media was replaced with supplemented DMEM. Where 
necessary cells were grown on coated cover-slips, washed in phosphate-buffered 
saline, fixed in paraformaldehyde and visualised using a Leica con-focal microscope 
at 488nm. 
Measurement of phospholipase D activity 
HEK-293 cells, transfected as described, were quiesced and labelled with 
2Ci/ml [3H] palmitic acid overnight (0.1%BSA, 0.1M HEPES pH7.4), washed twice 
with 0.1%BSA, 0.1M HEPES, pH7.4 and incubated with 0.3% butan-1-ol for 15 
minutes. Cells were stimulated with phorbol ester (PMA) for 30 minutes and lipids 
extracted with ice-cold methanol, chloroform and water. The lipid phase was dried 
under N2 gas and re-suspended in chloroform prior to separation by thin layer 
chromatography (TLC) developed in chloroform:methanol:acetone:acetic acid and 
phosphatidylbutanol (PtdBut) was visualised in iodine vapour scraped and counted 
(expressed as percentage of total lipid labelling).
3. RESULTS
Searches of the protein sequences of human PLD1b and PLD2a with two consensus 
motifs for caspase 3 cleavage (DXXD or D/E, D/E, X, D) [20] identified several 
putative sites. The Predictor of Protease Specificity (PoPS) web-based bioinformatics 
tool provided quantitative scores for the putative caspase cleavage sites within PLD 
sequences. Within PoPS, caspase 3 sites are defined using four residues N-terminal 
(S4-S1) and one residue C-terminal (S1’) to the cleaved peptide bond to give a 
maximum achievable score of 25.  PoPS analysis identified 3 putative caspase-3 sites 
(with scores above 15) in the protein sequence of human PLD1b and 2 putative sites 
in human PLD2a (Figure 1A).  All of these sites had been identified using the 
consensus sequence approach. 
In human PLD1b, two of the putative caspase sites are located in the ‘loop 
region’ at DDVD549S and DFID631R between the PLD domains (Figure 1B). The 
remaining caspase 3 site in the N-terminus of PLD1b at EEVD41Y, is known to be the 
region of PKC interaction and phosphorylation sites (Figure 1B) [17]. Two high-
scoring putative caspase-3 sites were also identified in the N-terminus of human 
PLD2a (Figure 1A) at DELD16S and DEVD28T. Of the 3 caspase sites identified in 
human PLD1b, DFID669R is conserved in the rat, but not the mouse, PLD1 sequence. 
Of the 2 caspase-3 sites found in human PLD2a, DEVD28T is conserved within the 
mouse but not rat PLD2 sequences. Analysis of the sequences of phospholipases C 
() and various phospholipase A2 variants demonstrated that the occurrence of 
these putative caspase 3 sites is specific to phospholipases D (results not shown). 
To determine if PLD1b was a caspase-3 substrate, purified recombinant and 
catalytically active [6,17] GST-PLD1b (1g) was incubated with purified 
recombinant caspase-3 (100ng) at 37oC for 0-60 minutes and PLD1b fragments 
separated by SDS-PAGE and detected by western blotting with commercial 
antibodies against an internal PLD1b sequence (Biosource; PLD1b residues 523-540) 
and the C-terminus (Santa Cruz).  Figure 1C shows that human recombinant PLD1b is 
rapidly (within 10 minutes) cleaved by caspase-3 in to two fragments; one of 75-
90kDa (F1) recognised by the internal antibody and one of 50-60kDa (F2) recognised 
by the C-terminal antibody. The sizes of the produced fragments were consistent with 
cleavage of GST-hPLD1b at one of the two centrally placed putative caspase-3 sites, 
rather than D41. PLD1b degradation was inhibited by pre-incubating caspase-3 with 
the competitive peptide inhibitor Ac-DEVD-Cho [22], but not prevented by inclusion 
of excess free glutathione S-transferase. The larger PLD1b fragment (75-90kDa) was 
also identified by antibodies raised against the N-terminal of PLD1b (Biosource) and 
by an anti-GST (Sigma; results not shown), suggesting that it consisted of at least 
residues 1-540 of PLD1b and the intact GST tag. GST-hPLD1b remained caspase-3 
sensitive at caspase to PLD1b ratios of 1:25 and 1:100 (results not shown).
To identify which aspartate residues were responsible for directing caspase-
mediated cleavage of PLD1b, D41, D545 and D631 were mutated to alanine and proteins 
expressed by coupled in vitro transcription and translation in the presence of 35S-
methionine. Labelled PLD1b proteins were incubated with caspase-3 and fragments 
separated by SDS-PAGE prior to identification and qunatification by phosphorimage 
analysis. Figure 2A shows that wild type GFP-PLD1b is successfully expressed in 
vitro and is rapidly degraded by caspase-3 to two fragments; one of 75-90kDa (F1) 
and one of approximately 50kDa (F2). Mutation of D545 to alanine renders PLD1b 
insensitive to caspase-mediated cleavage whereas mutation of D631 does not prevent 
cleavage. Cleavage is specific to caspase-3 since pre-incubation of caspase 3 with the 
peptide competitive inhibitor (Ac-DEVD-Cho) prevents PLD1b degradation. 
Mutation of D41 to alanine did not prevent cleavage of PLD1b (results not shown). 
Figure 2b shows quantification of radioactivity within the 148kDa parent GFP-
hPLD1b (wild-type and mutants) band following incubation with caspase-3 from 3 
separate experiments. As a control human GFP-hPLD2a (134kDa) was also expressed 
using in vitro coupled transcription and translation. Mutation of D16, but not D28, to 
alanine renders human PLD2a caspase-3 insensitive (Fig. 2C and 2D). Figure 3A 
shows that approximately half of the in vitro produced GFP-PLD1b protein (at 
148kDa) is degraded by caspase-3 within 10 minutes with a concomitant increase in 
radioactivity in the 70-80kDa fragment (F1). Degradation of GFP-PLD1b is 
dependent on caspase-3 concentration with near maximal levels of degradation 
occurring at 15-20nM caspase 3 (Fig. 3B). 
GFP, GFP-PLD1b or GFP-PLD1bD545A and GFP-PLD1bD631Awere 
successfully expressed by transient transfection of human embryonic kidney cells 
(HEK-293) as determined by con-focal microscopy. Figure 4A shows that GFP is 
more weakly expressed than wild type PLD1b or the PLD1b mutants. Phorbol ester-
stimulated PLD activation was measured in HEK 293 cells expressing GFP alone. 
The results in figure 4B show that increasing concentrations of phorbol ester result in 
a 4-fold increase in PLD activity as determined by formation of phosphatidylbutanol. 
Transfection of HEK-293 with GFP-PLD1b wt or PLD1b mutants resulted in an 
approximate 3-fold increase in basal activity that was statistically significant. 
However, only wild type-GFP-PLD1b and GFP-PLD1bD545A showed phorbol ester 
sensitive increases in PLD activity following transfection, mutation of D631 to alanine 
rendered this mutant insensitive to subsequent phorbol ester mediated stimulation. 
HEK-293 cells expressing wild-type GFP-PLD1b were initiated in to 
apoptosis by UV-light treatment and phorbol ester-stimulated phosphatidylcholine 
hydrolysis was measured over 24 hours. During this period there was a 4-fold increase 
in caspase activity (results not shown) and at 24 hours the cells showed a significant 
amount of apoptotic phenotypes including membrane blebbing and nuclear 
condensation and fragmentation (results not shown). In cells expressing wild-type 
PLD1b, PMA-stimulated phosphatidylcholine hydrolysis initially declined after UV 
treatment but was followed by a sustained rise in PtdBut accumulation between 4-12 
hours (Fig. 4C). Whilst the initial decline in phosphatidylcholine hydrolysis was also 
apparent in apoptosing cells expressing hPLD1bD545A, much of the second sustained 
phase of phosphatidylcholine hydrolysis observed between 4 and 12 hours was lost 
(Fig. 4C). This data suggests that over-expression of a caspase-resistant form of 
PLD1b reduces the progress of phosphatidylcholine hydrolysis in apoptosing cells. 
4. DISCUSSION
Both human PLD1b and PLD2a contain previously unrecognised caspase 3 
cleavage sites not present in rat or mouse phospholipases D. In PLD2a, the caspase 3 
site is located in the N-terminus at residue D16 whereas in hPLD1b, the caspase 3 
cleavage site is located in the loop region between the HKD motifs at residue D549. 
The caspase motif identified in PLD1b (DEVD545S) is similar the classical caspase 
site identified in DNA topioisomerase I (DEVD) cytosolic PLA2 (DELD) and 
cleavage at this site is inhibited by the known peptide competitor DDVD [22,38,39]. 
Structure and functional analysis has shown that PLD1b activity can be reconstituted 
when the ORF is separated (genetically) within the loop region and the two halves co-
expressed within cells [40]. This observation has lead to the suggestion that 
interaction of the HKD motifs in the PLD domains, via folding of the loop region, is 
necessary for catalytic activity [1,40]. Our data suggests that caspase-mediated 
cleavage of PLD1b could provide a post-translational mechanism that mimics this 
observation. 
Whilst mutation of D549 to alanine in PLD1b did not affect phorbol ester 
activation of PLD1b in HEK 293 cells, mutation of D631 to alanine prevented 
stimulation of phosphatidylcholine hydrolysis. This data suggests that within the loop 
region D631 plays a role in regulating activation of PLD1b. Since the PKC binding and 
phosphorylation sites within PLD1b and located in the extreme N-terminus [17], the 
mechanism by which this mutation prevents phosphatidylcholine hydrolysis is not 
clear.
Expression of the caspase-3 resistant form of PLD1b reduced the extent of 
UV-initiated phosphatidylcholine hydrolysis in HEK 293 cells undergoing apoptosis. 
Apoptosis involves a complex interplay of irreversible changes to the plasma-
membrane, cytoskeleton and nucleus and our data suggest that PLD activity may 
either be targeted for destruction to facilitate these changes or through caspase-
mediated degradation become deregulated and therefore able to play a role in 
facilitating apoptotic changes.
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LEGENDS
Figure 1. Human PLD is a potential caspase-3 substrate.
(A) Putative caspase-3 cleavage sites in human PLD1b and PLD2a were identified 
and scored (out of 25) using PoPS. (B) Purified recombinant GST-PLD1b (1g) was 
incubated with caspase 3 (100ng) for up to 60 minutes with or without Ac-DEVD-
Cho inhibitor (2M) or excess recombinant GST (xsr-GST - 2.5g) and fragments 
separated by SDS-PAGE (4-12%) prior to identification by western blotting with 
hPLD1 specific antibodies raised to an internal sequence (Biosource) or the C-
terminal of PLD1b (Santa Cruz) and ECL. (C) A schematic representation of the 
human PLD1b sequence showing the positions of PX, PH and PLD domains, putative 
caspase-3 cleavages sites and antibody epitopes. 
Figure 2. Identification of caspase-3 motifs PLD1b and PLD2a
Wild-type and mutated forms of human GFP-PLD1b (A) and GFP-PLD2a (B) were 
expressed in vitro in the presence of 35S-methionine. Produced proteins were 
incubated at 37oC for 60 minutes with caspase-3 with or without pre-incubation with 
peptide inhibitor and labelled fragments (F1 and F2 for PLD1b and F3 and F4 for 
PLD2a) separated by SDS-PAGE prior to visualisation and quantification by 
phosphorimaging (results for PLD1b-panel C, PLD2a -panel D). Images are 
representative of 3 experiments and bars charts show mean radioactivity remaining in 
the parent PLD band (1b/2a) as a % of total, +/- SEM. Luciferase (61kDa) expression 
was a control for the coupled transcription and translation process. 
Figure 3. Caspase 3 catalysed cleavage of PLD1b is both time and dose –
dependent. 
Wild type human GFP-PLD1b was expressed in vitro as described. (A) Produced 
PLD1b protein was incubated at 37oC for up to 120 minutes with caspase 3 (25nM). 
(B) Produced PLD1b protein was incubated at 37oC for 120 minutes with caspase 3 
(0-50nM). Labelled fragments were separated and quantified as before. Graphs show 
mean radioactivity remaining in the parent PLD1b band (148kDa) in the 70-90kDa 
(F1) band as a % of total, +/- SEM from 3 experiments. 
Figure 4. Expression of a caspase-3 resistant PLD1b in HEK-293 cells. 
HEK 293 cells transiently expressing GFP, GFP-hPLD1b , D545A or D631A were 
fixed and GFP-fluorescence localised by con-focal microscopy (panel A). Similarly 
transfected (GFP, GFP-hPLD1b-wild type, D545A or D631A) HEK-293 cells were 
labelled 3H-palmitate prior to stimulation with phorbol ester (0-300nM) in the 
presence of butan-1-ol (0.3%w/v). Accumulated phosphatidylbutanol (PtdBut) was 
separated by thin layer chromatography, extracted and quantified by scintillation 
counting. Results in panel B are means from triplicate determinations +/- SEM. HEK-
293 cells transiently transfected with pcDNA3.1 expressing GFP-hPLD1b or GFP-
hPLD1bD545A and labelled with 
3H-palmitate prior to initiation in to apoptosis by 
UV-light treatment. PMA-stimulated (300nM) phosphatidylbutanol accumulation was 
quantified over 24 hours (panel C) as means from triplicate determinations +/- SEM.
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